AP
BMRN icon

Advisors Preferred’s BioMarin Pharmaceuticals BMRN Stock Holding History

Advisors Preferred’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,329
Closed -$953K – 253
2024
Q4 		$953K Buy
+14,329
New +$960K 0.15% 77

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Advisors Preferred's BMRN Position: Q1 2025 in Review

Advisors Preferred sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2025, closing a stake of 14,329 shares — an estimated $953K sold.

Advisors Preferred first reported a position in BMRN in Q4 2024 and held it in 1 quarter. The position peaked at $953K in Q4 2024. 584 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

  • Advisors Preferred reported no remaining BioMarin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Advisors Preferred sold 14,329 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $953K.
  • Advisors Preferred first reported a position in BioMarin Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Advisors Preferred's BioMarin Pharmaceuticals position peaked at $953K in Q4 2024.
  • 584 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on Advisors Preferred's 13F filing for Q1 2025, filed 6 May 2025.